Compared Reversed US-Guided Dorsal Penile Nerve Block (RUSDPNB) with DPNB in Circumcisions for Pediatric Patients
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Nov 22, 2024
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain relief for boys undergoing circumcision, a common surgical procedure. The focus is on comparing a technique that uses ultrasound to guide the injection of anesthetic, called the Reversed Ultrasound-Guided Dorsal Penile Nerve Block (RUSDPNB), with the traditional method that uses anatomical landmarks to find the right spot for the injection, known as DPNB. The goal is to see if the ultrasound method provides better pain relief and fewer complications after surgery.
Boys aged 0 to under 18 who are scheduled for circumcision may be eligible to participate. If you choose to join the study, you will receive information about it ahead of time, and consent can be signed up to the day of the surgery. On the day of the procedure, you will meet the anesthesia team who will explain everything again. Participants will be randomly assigned to either the ultrasound group or the control group, but only the medical team will know which method each participant receives. Throughout the process, researchers will monitor pain levels and any side effects, as well as how much pain medication is needed after the operation. Importantly, participating in the trial will not change how your child's surgery is performed.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • male
- • undergoing circumcision
- • informed consent
- Exclusion Criteria:
- • other surgery than circumcision in the same time
- • contraindication to local anesthesia
- • allergy to bupivacaine
- • chronic opiates treatment
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported